Federal Register / Vol. 85, No. 248 / Monday, December 28, 2020 / Notices 84353 

119. Lisa Eisman, Norwalk, Connecticut, 

Court of Federal Claims No: 20– 

1664V 

120. William Ranks, Camp Verde, 

Arizona, Court of Federal Claims 

No: 20–1665V 

121. Nancy Richmond, Greenville, 

North Carolina, Court of Federal 

Claims No: 20–1666V 

122. Carol Kempkes, Des Moines, Iowa, 

Court of Federal Claims No: 20– 

1667V 

123. Anna-Lis Seevers, Big Rapids, 

Michigan, Court of Federal Claims 

No: 20–1669V 

124. Lisa Jackson, Englewood, Ohio, 

Court of Federal Claims No: 20– 

1670V 

125. Marilyn Duncan, Burkesville, 

Kentucky, Court of Federal Claims 

No: 20–1671V 

126. Mary Brown, Frankenmuth, 

Michigan, Court of Federal Claims 

No: 20–1672V 

127. Nina Watkins, Upper Marlboro, 

Maryland, Court of Federal Claims 

No: 20–1673V 

128. Thomas Ross, Olmsted Township, 

Ohio, Court of Federal Claims No: 

20–1674V 

129. Michele Hunter, Torrington, 

Connecticut, Court of Federal 

Claims No: 20–1675V 

130. Jacqueline Bowling, Pikeville, 

Kentucky, Court of Federal Claims 

No: 20–1676V 

131. Janet Sincebaugh, Williamsville, 

New York, Court of Federal Claims 

No: 20–1677V 

132. Stacey Neves on behalf of I. N., 

New York, New York, Court of 

Federal Claims No: 20–1678V 

133. Elisabeth Preitauer, Wichita Falls, 

Texas, Court of Federal Claims No: 

20–1679V 

134. Dominick Clemente, Brooklyn, 

New York, Court of Federal Claims 

No: 20–1680V 

135. Theresa Jackson, Boston, 

Massachusetts, Court of Federal 

Claims No: 20–1681V 

136. Charles Edwards, Lumberton, 

Texas, Court of Federal Claims No: 

20–1682V 

137. Charles Edwards, Lumberton, 

Texas, Court of Federal Claims No: 

20–1683V 

138. Barbara Lytes-Williams, Batesburg, 

South Carolina, Court of Federal 

Claims No: 20–1684V 

139. Yaneth Garcia on behalf of A.M., 

Williamsville, New York, Court of 

Federal Claims No: 20–1685V 

140. Frances Kraemer, Boston, 

Massachusetts, Court of Federal 

Claims No: 20–1687V 

141. Jane Robinson, Boston, 

Massachusetts, Court of Federal 

Claims No: 20–1688V 

142. Pavlo Chyshkevych and Nataliya 

Chyshkevych on behalf of R.C., 

Phoenix, Arizona, Court of Federal 

Claims No: 20–1689V 

143. Janet Burgo, Atlanta, Georgia, Court 

of Federal Claims No: 20–1691V 

144. Reginald Holmes, Clermont, 

Florida, Court of Federal Claims No: 

20–1693V 

145. Jean Cefalu, New Orleans, 

Louisiana, Court of Federal Claims 

No: 20–1694V 

146. Joel Nichols, North Billerica, 

Massachusetts, Court of Federal 

Claims No: 20–1695V 

147. Paul Wooters, Southlake, Texas, 

Court of Federal Claims No: 20– 

1696V 

148. Deborah Liter, Madison, Indiana, 

Court of Federal Claims No: 20– 

1697V 

149. Carrie Parent, Myrtle Beach, South 

Carolina, Court of Federal Claims 

No: 20–1698V 

150. Charles Stella, New York, New 

York, Court of Federal Claims No: 

20–1699V 

151. Pamela Havice, Boston, 

Massachusetts, Court of Federal 

Claims No: 20–1701V 

152. Anita Hall Darroca, Indianapolis, 

Indiana, Court of Federal Claims 

No: 20–1702V 

153. Regis Grice, Waupun, Wisconsin, 

Court of Federal Claims No: 20– 

1703V 

154. Stephen Vaccaro, Boston, 

Massachusetts, Court of Federal 

Claims No: 20–1704V 

155. Bill Tackett, Jr., Lutz, Florida, 

Court of Federal Claims No: 20– 

1705V 

156. Shakeyla Barber, Bronx, New York, 

Court of Federal Claims No: 20– 

1706V 

157. Teresa Davis, Boston, 

Massachusetts, Court of Federal 

Claims No: 20–1707V 

158. Clifford Gray, Antioch, Tennessee, 

Court of Federal Claims No: 20– 

1708V 

159. Barbara Benson, Dresher, 

Pennsylvania, Court of Federal 

Claims No: 20–1709V 

160. Nancy Dubrow, Beverly Hills, 

California, Court of Federal Claims 

No: 20–1710V 

[FR Doc. 2020–28548 Filed 12–23–20; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Meeting of the Advisory Committee on 

Interdisciplinary, Community-Based 

Linkages 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, this 

notice announces that the Advisory 

Committee on Interdisciplinary, 

Community-Based Linkages (ACICBL) 

will hold public meetings for the 2021 

calendar year (CY). Information about 

ACICBL, agendas, and materials for 

these meetings can be found on the 

ACICBL website at https://

www.hrsa.gov/advisory-committees/ 

interdisciplinary-community-linkages/ 

meetings/index.html. 

DATES: ACICBL meetings will be held 

on: 

• January 14, 2021, 10:00 a.m.–5:00 

p.m. Eastern Time (ET) and January 15, 

2021, 10:00 a.m.–5:00 p.m. ET; 

• February 17, 2021, 10:00 a.m.–5:00 

p.m. ET; and 

• August 5, 2021, 10:00 a.m.–5:00 

p.m. ET. 

ADDRESSES: Meetings may be held by 

teleconference, Adobe Connect webinar, 

and/or in-person. For updates on how 

the meetings will be held, visit the 

ACICBL website 30 business days before 

the date of the meeting, where 

instructions for joining meetings either 

in-person or remotely will also be 

posted. If a meeting is held in-person, it 

will be held at 5600 Fishers Lane, 

Rockville, Maryland 20857. For meeting 

information updates, go to the ACICBL 

website meeting page at https:// 

www.hrsa.gov/advisory-committees/ 

interdisciplinary-community-linkages/ 

index.html. 

FOR FURTHER INFORMATION CONTACT: 

Shane Rogers, Designated Federal 

Official, Division of Medicine and 

Dentistry, Bureau of Health Workforce, 

HRSA, 5600 Fishers Lane, Room 

15N142, Rockville, Maryland 20857; 

301–443–5260; or SRogers@hrsa.gov. 

SUPPLEMENTARY INFORMATION: The 

ACICBL provides advice and 

recommendations to the Secretary of 

HHS on policy, program development, 

and other matters of significance 

concerning the activities under sections 

750–760, Title VII, Part D of the Public 

Health Service (PHS) Act. The ACICBL 


tkelley on DSKBCP9HB2PROD with NOTICES
84354 Federal Register / Vol. 85, No. 248 / Monday, December 28, 2020 / Notices 

submits an annual report to the 

Secretary of HHS and to Congress 

describing its activities, including 

findings and recommendations made by 

the ACICBL concerning the activities 

under sections 750–760 of the PHS Act. 

Since priorities dictate meeting times, 

be advised that start times, end times, 

and agenda items are subject to change. 

For CY 2021 meetings, agenda items 

may include, but are not limited to, 

policy and program development and 

other significant matters related to 

activities authorized under Part D of the 

PHS Act as well as issues related to the 

pending Committee reports. Refer to the 

ACICBL website listed above for all 

current and updated information 

concerning the CY 2021 ACICBL 

meetings, including meeting times, draft 

agendas, and meeting materials that will 

be posted 30 calendar days before the 

meeting. 

Members of the public will have the 

opportunity to provide comments. 

Public participants may submit written 

statements in advance of the scheduled 

meeting(s). Oral comments will be 

honored in the order they are requested 

and may be limited as time allows. 

Requests to submit a written statement 

or make oral comments to the ACICBL 

should be sent to Shane Rogers using 

the contact information above at least 5 

business days before the meeting 

date(s). 

Individuals who need special 

assistance or another reasonable 

accommodation should notify Shane 

Rogers using the contact information 

listed above at least 10 business days 

before the meeting(s) they wish to 

attend. 

If a meeting is held in-person, it will 

occur in a federal government building 

and attendees must go through a 

security check to enter. Non-U.S. citizen 

attendees must notify HRSA of their 

planned attendance at an in-person 

meeting at least 20 business days prior 

to the meeting in order to facilitate their 

entry into the building. All attendees are 

required to present government-issued 

identification prior to entry. 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2020–28466 Filed 12–23–20; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Findings of Research Misconduct 

AGENCY: Office of the Secretary, HHS. 

ACTION: Notice. 

SUMMARY: Findings of research 

misconduct have been made against 

Yihong Wan, Ph.D. (Respondent), 

Associate Professor, Department of 

Pharmacology, University of Texas 

Southwestern Medical Center (UTSMC). 

Respondent engaged in research 

misconduct in research supported by 

U.S. Public Health Service (PHS) funds, 

specifically National Institute of 

Diabetes and Digestive and Kidney 

(NIDDK), National Institutes of Health 

(NIH), grant R01 DK089113. The 

administrative actions, including 

supervision for a period of three (3) 

years, were implemented beginning on 

December 8, 2020, and are detailed 

below. 

FOR FURTHER INFORMATION CONTACT: 

Elisabeth A. Handley, Director, Office of 

Research Integrity, 1101 Wootton 

Parkway, Suite 240, Rockville, MD 

20852, (240) 453–8200. 

SUPPLEMENTARY INFORMATION: Notice is 

hereby given that the Office of Research 

Integrity (ORI) has taken final action in 

the following case: 

Yihong Wan, Ph.D., University of 

Texas Southwestern Medical Center: 

Based on the report of an investigation 

conducted by UTSMC and additional 

analysis conducted by ORI in its 

oversight review, ORI found that 

Respondent, Associate Professor, 

Department of Pharmacology, UTSMC, 

engaged in research misconduct in 

research supported by PHS funds, 

specifically NIDDK, NIH, grant R01 

DK089113. 

ORI found that Respondent engaged 

in research misconduct by intentionally, 

knowingly, and/or recklessly falsifying 

and/or fabricating bone 

histomorphometry data by altering or 

creating Excel data table values for 

additional bone samples that did not 

exist or were not analyzed and by 

falsely stating means and standard 

deviations calculated from experiments 

with N values 

(i.e., number of mouse samples) that 

were larger than the actual N values in 

the following published paper: 

• miR–34a blocks osteoporosis and 

bone metastasis by inhibiting 

osteoclastogenesis and Tgif2. Nature 

2014;512(7515):431–5 (hereafter referred 

to as ‘‘Nature 2014’’). Retraction in: 

Nature 2020 Jun;582(7810):134. 

Specifically, ORI found that 

Respondent knowingly, intentionally, 

and/or recklessly falsified and/or 

fabricated bone histomorphometry data 

in eight (8) extended figures of one (1) 

published paper by manually falsifying 

and/or fabricating data values within 

multiple Excel spreadsheets and by 

creating increased N values without 

testing additional samples. Specifically: 

• In Extended Figure 1i of Nature 

2014, Respondent fabricated female 

vertebrae histomorphometry data by 

multiplying fourteen (14) different 

numerical values representing male 

mouse vertebrae data by a factor of 0.95 

to create female vertebrae values in one 

(1) Excel spreadsheet 

• in Extended Figures 1i, 2d, 3d, 3h, 

4h, 6a, 6e, and 9g of Nature 2014, 

Respondent falsified histomorphometry 

data for ninety-nine (99) data table 

values from two (2) Excel spreadsheets 

representing bone parameters for male 

distal femur, male vertebrae, female 

distal femur, and female vertebrae 

samples 

• in Extended Figure 4h of Nature 

2014, respondent fabricated bone 

histomorphometry data by reporting 

that the means and standard deviations 

were calculated from experiments with 

a value of six (6) to eight (8) mice per 

experimental condition, when 

respondent calculated the means and 

standard deviations from only three (3) 

mice (N = 3) 

Dr. Wan entered into a Voluntary 

Settlement Agreement (Agreement) and 

agreed to the following: 

(1) Respondent agreed to have her 

research supervised for a period of three 

(3) years beginning on December 8, 

2020. Respondent agreed that prior to 

the submission of an application for 

PHS support for a research project on 

which Respondent’s participation is 

proposed and prior to Respondent’s 

participation in any capacity on PHSsupported research, Respondent shall 

ensure that a plan for supervision of 

Respondent’s duties is submitted to ORI 

for approval. The supervision plan must 

be designed to ensure the scientific 

integrity of Respondent’s research 

contribution. Respondent agreed that 

she shall not participate in any PHSsupported research until such a 

supervision plan is submitted to and 

approved by ORI. Respondent agreed to 

maintain responsibility for compliance 

with the agreed upon supervision plan. 

(2) The requirements for Respondent’s 

supervision plan are as follows: 

i. A committee of 2–3 senior faculty 

members at the institution who are 

familiar with Respondent’s field of 

research, but not including 

Respondent’s supervisor or 

collaborators, will provide oversight and 

guidance for a period of three (3) years 

from the effective date of the 

Agreement. The committee will review 

primary data from Respondent’s 

laboratory on a quarterly basis and 

submit a report to ORI at six (6) month 


tkelley on DSKBCP9HB2PROD with NOTICES